---
document_datetime: 2025-03-04 11:28:11
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mirvaso-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mirvaso-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.9149565
conversion_datetime: 2025-12-18 09:13:09.010624
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Mirvaso

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                     |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0039              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 11/12/2024                          |                                             | SmPC, Annex II, Labelling and PL | To bring the annexes in line with QRD by removing from SmPC section 6.4 and the PL \"This medicinal product does not require any special storage condition.\" and from Annex II.B the description \"for renewable delivery\". In addition the MAH has included the E number for excipient Propylene Glycol in annex IIIA and to remove the local representative |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                 |            |            |                        | for UK (NI) and update the details for the local representatives in BE, LU, HU, MT, NL and RO. Also Annex A has been updated to correct the container description from \"pump\" to multidose container. The MAH also took this opportunity to align the translations with the approved EN annexes.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10093 /202402 | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                   | 03/10/2024 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                  |
| IA/0038             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                     | 09/08/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                                    |
| IA/0036             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                   | 30/04/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                                    |
| IA/0035             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                     | 08/08/2023 | n/a        |                        |                                                                                                                                                                                                                                                                                                    |
| IB/0034/G           | This was an application for a group of variations. B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid | 18/04/2023 | 01/02/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IAIN/0033/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 10/02/2023 | 01/02/2024 | Annex II and PL        |                                   |
| IA/0032             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                | 09/02/2022 | n/a        |                        |                                   |
| IB/0031             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                     | 20/01/2022 | n/a        |                        |                                   |
| IB/0030             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                             | 18/01/2022 | 23/01/2023 | SmPC, Labelling and PL |                                   |
| PSUSA/10093 /202102 | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                                                              | 30/09/2021 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0028             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                            | 07/01/2021   | n/a        |                       |                                                                                                                                                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10093 /202002 | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                          | 01/10/2020   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| IA/0026             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                            | 07/02/2020   | n/a        |                       |                                                                                                                                                                                                                                                                       |
| PSUSA/10093 /201902 | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                          | 05/09/2019   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| IB/0025             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                          | 09/07/2019   | n/a        |                       |                                                                                                                                                                                                                                                                       |
| IAIN/0023           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 25/04/2019   | 01/04/2020 | Annex II and PL       |                                                                                                                                                                                                                                                                       |
| R/0021              | Renewal of the marketing authorisation.                                                                                                                                                                                                | 20/09/2018   | 22/11/2018 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Mirvaso in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10093 /201802   | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                                                                     | 06/09/2018   | n/a        |             | PRAC Recommendation - maintenance   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------|
| IB/0019/G             | This was an application for a group of variations. B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                      | 17/05/2018   | n/a        |             |                                     |
| II/0017               | Update of section 4.8 of the SmPC in order to update the frequency of the adverse drug reaction (ADR) rosacea from 'uncommon' to 'common' following a re-examination of the frequency of ADRs in pertinent studies. The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/04/2018   | 22/11/2018 | SmPC and PL |                                     |
| IA/0018               | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                       | 27/03/2018   | n/a        |             |                                     |
| PSUSA/10093 /201708   | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                                                                     | 08/03/2018   | n/a        |             | PRAC Recommendation - maintenance   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10093 /201702   | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                             | 01/09/2017   | n/a        |                 | PRAC Recommendation - maintenance                                                                                                          |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0015             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                        | 15/06/2017   | n/a        |                 |                                                                                                                                            |
| PSUSA/10093 /201608   | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                             | 23/03/2017   | 24/05/2017 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10093/201608. |
| IAIN/0013/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 24/03/2017   | n/a        |                 |                                                                                                                                            |
| IAIN/0012/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                       | 20/02/2017   | 24/05/2017 | Annex II and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            |                        |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0011             | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                              | 12/01/2017 | 24/05/2017 | SmPC, Labelling and PL |                                                                                                                                            |
| IB/0009             | B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms                                                                                                                                                           | 16/12/2016 | 24/05/2017 | SmPC, Labelling and PL |                                                                                                                                            |
| PSUSA/10093 /201602 | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                               | 15/09/2016 | 11/11/2016 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10093/201602. |
| PSUSA/10093 /201508 | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                               | 17/03/2016 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10093 /201502 | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                               | 24/09/2015 | 19/11/2015 | SmPC, Annex II and PL  | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10093/201502. |
| PSUSA/10093 /201408 | Periodic Safety Update EU Single assessment - brimonidine (centrally authorised product only)                                                                                                                                                                                                                                               | 26/03/2015 | 02/06/2015 | SmPC and PL            | Please refer to Mirvaso PSUSA-10093-201408 EPAR: Scientific conclusions and grounds recommending the                                       |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                        | variation to the terms of the marketing authorisation.   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------|
| IAIN/0005   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 02/02/2015 | n/a        |                        |                                                          |
| IAIN/0003/G | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 14/11/2014 | n/a        |                        |                                                          |
| IB/0002/G   | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.5.a.1 - Change in pack size of the finished                                                                                                                                                                                                                                                                                                                                                                                             | 24/09/2014 | 02/06/2015 | SmPC, Labelling and PL |                                                          |

<div style=\"page-break-after: always\"></div>

|             | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |     |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IAIN/0001/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/03/2014 | n/a |